Public Employees Retirement System of Ohio Invests $16.82 Million in Edwards Lifesciences Corporation $EW

Public Employees Retirement System of Ohio purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, Holdings Channel reports. The institutional investor purchased 185,970 shares of the medical research company’s stock, valued at approximately $16,823,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of EW. BlackRock Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter valued at approximately $5,318,092,000. Varma Mutual Pension Insurance Co acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $11,168,000. Norges Bank acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $803,686,000. Conway Capital Management Inc. acquired a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $954,000. Finally, TD Asset Management Inc boosted its stake in Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock worth $66,335,000 after acquiring an additional 47,051 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several research analyst reports. Evercore reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Citigroup increased their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,501 shares of company stock worth $408,213 over the last three months. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Trading Up 0.3%

EW opened at $90.19 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market capitalization of $51.93 billion, a PE ratio of 51.83, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company’s 50-day moving average is $89.54 and its 200 day moving average is $85.03.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.